The FDA Proposes an Accelerated Approval Pathway for Alzheimer’s Disease Drugs
In an effort to speed the development of Alzheimer’s disease therapeutics, the FDA has now proposed an accelerated approval pathway (the New England Jounal of Medicine, March 13, 2013).
Alzinova’s Eurostars project AD-AIM earmarked for funding
The project E!7927 AD-AIM, in which Alzinova is the main participant, has been earmarked for funding within the Eurostars program.
Alzinova’s Eurostars project receives positive evaluation
The Eurostars project E!7927 AD-AIM, in which Alzinova is the main participant, has been positively evaluated by an independent evaluation panel of experts. Out of a total of 306 eligible applications, Alzinova’s project was ranked 34.
Alzinova is Featured in the December 17 Issue of BioCentury, the Bernstein Report on BioBusiness
The article entitled Alzinova: Freezing out AD briefly presents Alzinova and its ALZ-101 vaccine candidate under the section Emerging Company Profile.
BioCentury is a leading provider of information, analysis and data on issues essential to life science ventures. Its flagship publication, BioCentury, the Bernstein Report on BioBusiness, serves a worldwide audience in the biopharma, investment and public policy communities.
Alzinova receives support from the Region of Västra Götaland
Alzinova has been granted support from the Region of Västra Götaland in the form of a favorable conditional loan. The loan will subsidize costs associated with the verification of Alzinova’s technology and business development activities in a project entitled “VAT” (Verification of Alzheimer’s Therapy).
Eli Lilly & Co’s Solanezumab Phase 3 Trial Validates Amyloid-β Hypothesis
Cautious optimism surrounds the Alzheimer’s disease immunotherapy field after Eli Lilly & Co reported the outcome of a Phase 3 trial on an anti-amyloid-β antibody, Solanezumab. The antibody had a small positive effect and is, in fact, the first example of a disease modifying effect on Alzheimer’s disease patients. The data has been analyzed by independent experts, and the effect indeed appears to be small, but real (read more on Alzforum.org).
Alzinova Establishes an International Scientific Advisory Board
Alzinova has established a scientific advisory board of renowned Alzheimer’s disease researchers.
Independent Research Substantiates Alzinova’s Technology
Researchers from the University of Leipzig and the Martin-Luther-Universität Halle-Wittenberg in Germany published an article today that substantiates the scientific rationale behind Alzinova’s Aβ oligomer mimics.
Alzinova Closes a Round of Share Issuance to Selected Investors
A round of priority issuing of shares was closed today. 100% of the shares were subscribed to selected business angels and GU Holding AB, the holding company at the University of Gothenburg.
Alzinova Holds Its First Shareholders’ Meeting
The first Shareholder’s Meeting in Alzinova was held today.
A new board of directors was elected and a new corporation charter approved.
Alzinova Acquires IPR
MIVAC Development AB and the inventors of the AβCC peptide™ technology today reached an intellectual property transfer agreement, whereby this invention and its intellectual property rights are transferred to Alzinova AB.
MIVAC Development and Alzinova AB also reached an agreement on transfer of IPR relating to a monoclonal antibody, ALZ-201, developed by MIVAC Development by implementation of the AβCC peptide™ technology.
The acquired IPR provides Alzinova with long-term capabilities of research and development of Alzheimer’s disease therapeutics and research tools.